Skip to main content
Eton Pharmaceuticals, Inc. logo

Eton Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ETON ISIN · US29772L1089 US Manufacturing
Open in API
Filings indexed 358 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country US United States of America
Listing US ETON

About Eton Pharmaceuticals, Inc.

https://etonpharma.com/

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company's strategy involves sourcing, acquiring, and developing therapies to serve small, underserved patient populations. Eton manages the complete drug development lifecycle, from navigating clinical trials and the regulatory approval process to bringing the final products to market. It actively seeks meaningful therapies from a global network of partners to build a diversified portfolio of treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is a Form 8-K “Current Report” disclosing Items 1.01 (entry into a material definitive agreement) and 2.01 (completion of asset acquisition/disposition). It is not an earnings release, interim or annual report, proxy, capital raising, M&A filing, or management change notice, but rather a routine SEC regulatory disclosure of a supply and distribution agreement. It therefore falls into the general 'Regulatory Filings' category.
2026-05-19 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
FORM 8-K
Earnings Release Classification · 90% confidence The document is a Form 8-K current report furnishing a press release with first quarter financial results (Item 2.02 Results of Operations and Financial Condition). It announces the company’s quarterly earnings, non-GAAP measures discussion, and cites Exhibit 99.1 as the earnings press release. This matches an Earnings Release, not a full interim report or management discussion. Therefore, ER is appropriate. Q1 2026
2026-05-14 English
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 27, 2026. It announces a press release about a pilot study for a product candidate but does not contain financial statements or detailed financial data. The document length is 3116 characters, which is relatively short and includes a press release as an exhibit. The content is an announcement of an event rather than a full financial report or detailed management discussion. According to the rules, such filings that announce events or press releases without substantive financial data or detailed reports are best classified as Regulatory Filings (RNS).
2026-04-27 English
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 16, 2026, for Eton Pharmaceuticals, Inc. The key content is the announcement of the appointment of Judith Matthews as Executive Vice President, Accounting and Finance, who will become CFO effective June 1, 2026, succeeding the current CFO. This is a clear announcement of a change in senior management. There is no financial data or report content, only a management change disclosure. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 5357 characters, which is sufficient for a detailed announcement but does not contain financial statements or earnings data. Hence, the classification is MANG with high confidence.
2026-04-16 English
10-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
Annual Report FY 2025
2026-03-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.